Immune to Cancer: The CRI Blog
-
CRI Funded Scientist
Samantha B Kemp, PhD
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a five-year survival rate of only 10%. There… -
CRI Funded Scientist
Qiming Zhang, PhD
Age is a dominant risk factor for cancer in humans and laboratory animals, with ~50% of all… -
CRI Funded Scientist
Nicholas F Kuhn, PhD
Cancer has many pernicious characteristics. At its inception, most cancers start to build a fort where they… -
CRI Funded Scientist
Jesusa Capera-Aragones, PhD
T lymphocytes patrol in our body continuously scanning for specific pathogens or cancerous cells. If an infected… -
CRI Funded Scientist
Peng Jiang, PhD
Cellular immunotherapy is a new form of anticancer treatment that engineers T cells to kill tumors that… -
CRI Funded Scientist
Tamar Lea Ben Shaanan, PhD
The lung and respiratory system are the principal interface with the inhaled environment. Protecting this barrier site… -
CRI Funded Scientist
Xin He, PhD
Interleukin-6 (IL-6) is a powerful product of our immune system that acts like a hormone circulating in… -
CRI Funded Scientist
Emanuele Lettera, PhD
Activation of the immune system is an important consequence of normal and tumor tissue exposure to cancer… -
CRI Funded Scientist
Chang Liao, PhD
Colorectal cancers represent a significant public health issue. Despite screening, available treatments, and increased awareness of lifestyle-related…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.